Kringle Pharma is a pioneering biopharmaceutical company dedicated to the development of HGF drugs for practical use. With a mission to create new value through HGF drugs, Kringle Pharma aims to contribute to the well-being of people worldwide. As a late-stage regenerative drug biotech venture, Kringle Pharma is currently conducting clinical trials focusing on various refractory diseases, especially rare diseases.

The company's strength lies in its platform for producing HGF proteins of pharmaceutical grade. HGF is a natural protein with multiple functions that protect and regenerate organs and tissues. Leveraging this platform, Kringle Pharma is driving the development of therapeutic drugs for refractory diseases.

With a dedication to helping patients suffering from serious illnesses, Kringle Pharma is at the forefront of delivering groundbreaking treatment options using HGF proteins. Contact Kringle Pharma today to learn more about their innovative research and development efforts in the field of regenerative medicine